Characteristics of patients receiving apixaban or warfarin as outpatient therapy for VTE
| . | Overall . | Subgroups . | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Provoked . | Unprovoked . | DVT only . | PE ± DVT . | ||||||||||||
| Apixaban (n = 20 561) . | Warfarin (n = 35 080) . | P . | Apixaban (n = 4894) . | Warfarin (n = 8585) . | P . | Apixaban (n = 15 667) . | Warfarin (n = 26 495) . | P . | Apixaban (n = 12 294) . | Warfarin (n = 19 720) . | P . | Apixaban (n =8267) . | Warfarin (n = 15 360) . | P . | |
| Qualifying VTE encounter, % | |||||||||||||||
| Setting | |||||||||||||||
| Acute-care inpatient | 47.6 | 70.8 | <.001 | 47.3 | 71.4 | <.001 | 47.7 | 70.5 | <.001 | 29.3 | 55.8 | <.001 | 74.9 | 90.0 | <.001 |
| Ambulatory care | 52.4 | 29.2 | — | 52.7 | 28.6 | — | 52.3 | 29.5 | — | 70.7 | 44.2 | — | 25.1 | 10.0 | — |
| Diagnosis | |||||||||||||||
| PE ± DVT | 40.2 | 43.8 | <.001 | 36.4 | 40.7 | <.001 | 41.4 | 44.8 | <.001 | — | — | — | 100.0 | 100.0 | — |
| PE with DVT | 21.5 | 22.2 | .170 | 19.4 | 20.7 | .275 | 22.0 | 22.7 | .301 | — | — | — | 21.5 | 22.2 | .170 |
| PE without DVT | 78.5 | 77.8 | — | 80.6 | 79.3 | — | 78.0 | 77.3 | — | — | — | — | 78.5 | 77.8 | — |
| DVT only | 59.8 | 56.2 | — | 63.6 | 59.3 | — | 58.6 | 55.2 | — | 100.0 | 100.0 | — | — | — | — |
| Presumed etiology | |||||||||||||||
| Provoked | 23.8 | 24.5 | .075 | 100.0 | 100.0 | — | — | — | — | 25.3 | 25.8 | .335 | 21.5 | 22.7 | .031 |
| Unprovoked | 76.2 | 75.5 | — | — | — | — | 100.0 | 100.0 | — | 74.7 | 74.2 | — | 78.5 | 77.3 | — |
| Patient | |||||||||||||||
| Age, y | |||||||||||||||
| Mean (SD) | 60.2 (16.4) | 60.5 (16.5) | .065 | 57.6 (17.7) | 57.2 (17.7) | .260 | 61.1 (15.9) | 61.6 (15.9) | .002 | 60.2 (16.6) | 60.2 (16.7) | .958 | 60.3 (16.1) | 60.9 (16.2) | .008 |
| Median | 60 | 60 | — | 58 | 58 | — | 61 | 61 | — | 60 | 60 | — | 61 | 61 | — |
| Age, % | |||||||||||||||
| 18-49 y | 24.7 | 24.5 | <.001 | 31.7 | 32.5 | .223 | 22.5 | 22.0 | <.001 | 24.9 | 25.7 | <.001 | 24.5 | 23.0 | .001 |
| 50-64 y | 37.6 | 36.0 | — | 35.0 | 34.0 | — | 38.4 | 36.6 | — | 37.9 | 35.9 | — | 37.2 | 36.2 | — |
| 65-74 y | 17.6 | 18.2 | — | 15.0 | 15.9 | — | 18.4 | 19.0 | — | 17.3 | 17.2 | — | 18.0 | 19.6 | — |
| ≥75 y | 20.1 | 21.2 | — | 18.3 | 17.5 | — | 20.6 | 22.4 | — | 20.0 | 21.3 | — | 20.3 | 21.2 | — |
| Sex, % | |||||||||||||||
| Male | 51.5 | 50.9 | .192 | 36.5 | 38.2 | .050 | 56.2 | 55.0 | .036 | 52.5 | 52.5 | .448 | 49.9% | 48.9% | .114 |
| Female | 48.5 | 49.1 | — | 63.5 | 61.8 | — | 43.8 | 45.0 | — | 47.5 | 47.5 | — | 50.1% | 51.1% | — |
| Deyo-Charlson Comorbidity Index,22 mean (SD) | 1.0 (1.7) | 1.2 (1.8) | <.001 | 1.3 (1.9) | 1.4 (2.0) | .004 | 0.9 (1.6) | 1.1 (1.7) | <.001 | 1.1 (1.7) | 1.3 (1.9) | <.001 | 1.0 (1.6) | 1.1 (1.7) | <.001 |
| . | Overall . | Subgroups . | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Provoked . | Unprovoked . | DVT only . | PE ± DVT . | ||||||||||||
| Apixaban (n = 20 561) . | Warfarin (n = 35 080) . | P . | Apixaban (n = 4894) . | Warfarin (n = 8585) . | P . | Apixaban (n = 15 667) . | Warfarin (n = 26 495) . | P . | Apixaban (n = 12 294) . | Warfarin (n = 19 720) . | P . | Apixaban (n =8267) . | Warfarin (n = 15 360) . | P . | |
| Qualifying VTE encounter, % | |||||||||||||||
| Setting | |||||||||||||||
| Acute-care inpatient | 47.6 | 70.8 | <.001 | 47.3 | 71.4 | <.001 | 47.7 | 70.5 | <.001 | 29.3 | 55.8 | <.001 | 74.9 | 90.0 | <.001 |
| Ambulatory care | 52.4 | 29.2 | — | 52.7 | 28.6 | — | 52.3 | 29.5 | — | 70.7 | 44.2 | — | 25.1 | 10.0 | — |
| Diagnosis | |||||||||||||||
| PE ± DVT | 40.2 | 43.8 | <.001 | 36.4 | 40.7 | <.001 | 41.4 | 44.8 | <.001 | — | — | — | 100.0 | 100.0 | — |
| PE with DVT | 21.5 | 22.2 | .170 | 19.4 | 20.7 | .275 | 22.0 | 22.7 | .301 | — | — | — | 21.5 | 22.2 | .170 |
| PE without DVT | 78.5 | 77.8 | — | 80.6 | 79.3 | — | 78.0 | 77.3 | — | — | — | — | 78.5 | 77.8 | — |
| DVT only | 59.8 | 56.2 | — | 63.6 | 59.3 | — | 58.6 | 55.2 | — | 100.0 | 100.0 | — | — | — | — |
| Presumed etiology | |||||||||||||||
| Provoked | 23.8 | 24.5 | .075 | 100.0 | 100.0 | — | — | — | — | 25.3 | 25.8 | .335 | 21.5 | 22.7 | .031 |
| Unprovoked | 76.2 | 75.5 | — | — | — | — | 100.0 | 100.0 | — | 74.7 | 74.2 | — | 78.5 | 77.3 | — |
| Patient | |||||||||||||||
| Age, y | |||||||||||||||
| Mean (SD) | 60.2 (16.4) | 60.5 (16.5) | .065 | 57.6 (17.7) | 57.2 (17.7) | .260 | 61.1 (15.9) | 61.6 (15.9) | .002 | 60.2 (16.6) | 60.2 (16.7) | .958 | 60.3 (16.1) | 60.9 (16.2) | .008 |
| Median | 60 | 60 | — | 58 | 58 | — | 61 | 61 | — | 60 | 60 | — | 61 | 61 | — |
| Age, % | |||||||||||||||
| 18-49 y | 24.7 | 24.5 | <.001 | 31.7 | 32.5 | .223 | 22.5 | 22.0 | <.001 | 24.9 | 25.7 | <.001 | 24.5 | 23.0 | .001 |
| 50-64 y | 37.6 | 36.0 | — | 35.0 | 34.0 | — | 38.4 | 36.6 | — | 37.9 | 35.9 | — | 37.2 | 36.2 | — |
| 65-74 y | 17.6 | 18.2 | — | 15.0 | 15.9 | — | 18.4 | 19.0 | — | 17.3 | 17.2 | — | 18.0 | 19.6 | — |
| ≥75 y | 20.1 | 21.2 | — | 18.3 | 17.5 | — | 20.6 | 22.4 | — | 20.0 | 21.3 | — | 20.3 | 21.2 | — |
| Sex, % | |||||||||||||||
| Male | 51.5 | 50.9 | .192 | 36.5 | 38.2 | .050 | 56.2 | 55.0 | .036 | 52.5 | 52.5 | .448 | 49.9% | 48.9% | .114 |
| Female | 48.5 | 49.1 | — | 63.5 | 61.8 | — | 43.8 | 45.0 | — | 47.5 | 47.5 | — | 50.1% | 51.1% | — |
| Deyo-Charlson Comorbidity Index,22 mean (SD) | 1.0 (1.7) | 1.2 (1.8) | <.001 | 1.3 (1.9) | 1.4 (2.0) | .004 | 0.9 (1.6) | 1.1 (1.7) | <.001 | 1.1 (1.7) | 1.3 (1.9) | <.001 | 1.0 (1.6) | 1.1 (1.7) | <.001 |